青蒿素抗瘧藥市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Artemisinin Antimalarial Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月16日 | 出版商:

Global Market Insights Inc. | 英文 102 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球青蒿素抗瘧藥物市場價值為 6.722 億美元，預計 2024 年至 2032 年複合年成長率為 4.2%。例如，美國疾病管制與預防中心報告稱，2022年，全球約有2.49億瘧疾病例，導致60.8萬人死亡。這些令人震驚的統計數據凸顯了對有效治療的需求增加，推動了青蒿素抗瘧藥物市場的成長。

基於青蒿素的聯合療法（ACT）作為瘧疾治療的黃金標準的崛起在市場擴張中發揮了關鍵作用。持續的研究和開發工作旨在增強這些藥物的功效和安全性。瘧疾診斷的進步進一步刺激了市場成長。在世界衛生組織等國際實體的支持下，全球對消除瘧疾的承諾凸顯了市場的重要性。此外，人們對瘧疾早期診斷和治療認知的提高擴大了對青蒿素療法的需求，推動了市場的發展勢頭。

整個青蒿素抗瘧藥物產業根據瘧疾類型、產品、類型和地區進行細分。

2023 年，惡性瘧原蟲細分市場以 5.538 億美元的估值引領市場。作為毒性最強的引起瘧疾的寄生蟲，惡性瘧原蟲由於其普遍且嚴重的感染而佔有相當大的市場佔有率。鑑於其在清除寄生蟲和降低死亡率方面的快速功效，基於青蒿素的聯合療法（ACT）成為惡性瘧原蟲瘧疾的第一線治療方法。惡性瘧原蟲瘧疾的顯著負擔，特別是在撒哈拉以南非洲和東南亞，刺激了對這些治療方法的需求。因此，青蒿素抗瘧藥物市場主要是由解決惡性瘧原蟲的必要性決定的，從而鞏固了其在治療領域的主導地位。

到了2023年，抗瘧藥片細分市場佔據80.5%的主導市場佔有率，這主要是由於其在瘧疾治療中的廣泛應用和已被證明的療效。這些片劑由蒿甲醚和苯芴醇等強效青蒿素衍生物配製而成，因其強大的抗瘧作用和易於服用而受到青睞。它們融入國民治療指南，再加上公共衛生系統和私人市場的可用性，鞏固了其領先的市場地位。

2023 年，中東和非洲市場價值為2.315 億美元，預計2024 年至2032 年複合年成長率為4.1%。流行的瘧疾病例。在政府和非政府組織的支持下，正在進行的抗擊瘧疾的健康措施增強了市場的存在。對醫療保健基礎設施的投資、瘧疾預防意識的提高以及以青蒿素為基礎的聯合療法 (ACT) 的可及性的提高，進一步擴大了該地區的市場佔有率。這些要素，加上加強治療效果和藥物可近性的策略重點，凸顯了中東和非洲地區在全球市場中的關鍵角色。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 9 章：公司簡介

AdvaCare Pharma USA LLC
Calyx Chemicals and Pharmaceuticals Ltd.
Cipla Limited
Guilin Pharmaceutical Co., Ltd.
Ipca Laboratories Ltd.
KPC Pharmaceuticals, Inc.
Novartis AG
Rusan Pharma Ltd.
Sanofi S.A.
Shin Poong Pharmaceutical Co., Ltd.

簡介目錄

Product Code: 10811

The Global Artemisinin Antimalarial Drugs Market was valued at USD 672.2 million in 2023 and is projected to grow at a CAGR of 4.2% from 2024 to 2032. The demand for effective malaria treatments has surged, especially in tropical and subtropical regions, due to the rising incidence of the disease. For example, the CDC reported that in 2022, there were approximately 249 million global malaria cases, resulting in 608,000 deaths. These alarming statistics underscore the heightened demand for effective treatments, propelling the growth of the artemisinin antimalarial drugs market.

The rise of artemisinin-based combination therapies (ACTs) as the gold standard for malaria treatment has played a pivotal role in market expansion. Continuous research and development efforts aim to bolster the efficacy and safety profiles of these drugs. Advancements in malaria diagnostics further stimulate market growth. The global commitment to eradicating malaria, supported by international entities like the World Health Organization, underscores the market's significance. Additionally, heightened awareness regarding early malaria diagnosis and treatment amplifies the demand for artemisinin-based therapies, propelling the market's momentum.

The overall artemisinin antimalarial drugs industry is segmented based on malaria type, product, type, and region.

In 2023, the Plasmodium falciparum segment led the market with a valuation of USD 553.8 million. As the most virulent malaria-causing parasite, Plasmodium falciparum commands a substantial market share due to its prevalent and severe infections. Given their rapid efficacy in clearing the parasite and reducing mortality, artemisinin-based combination therapies (ACTs) serve as the frontline treatment for P. falciparum malaria. The pronounced burden of P. falciparum malaria, especially in Sub-Saharan Africa and Southeast Asia, fuels the demand for these treatments. Thus, the artemisinin antimalarial drugs market is predominantly shaped by the imperative to address P. falciparum, solidifying its leading role in the therapeutic domain.

The antimalarial tablets segment commanded a dominant market share of 80.5% in 2023, largely due to their widespread application and proven efficacy in malaria treatment. Formulated with potent artemisinin derivatives like artemether and lumefantrine, these tablets are favored for their robust antimalarial effects and ease of administration. Their integration into national treatment guidelines, coupled with availability across public health systems and private markets, cements their leading market position.

In 2023, the Middle East and Africa market was valued at USD 231.5 million and is projected to grow at a CAGR of 4.1% from 2024 to 2032. The MEA region's substantial share in the artemisinin antimalarial drugs market is attributed to the prevalent malaria cases in several of its countries. Ongoing health initiatives to combat malaria, supported by governmental and non-governmental organizations, fortify the market's presence. Investments in healthcare infrastructure, heightened awareness of malaria prevention, and increased accessibility to artemisinin-based combination therapies (ACTs) further amplify the region's market share. These elements, alongside a strategic emphasis on enhancing treatment outcomes and drug accessibility, highlight the MEA region's pivotal role in the global market.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 High prevalence of malaria
  - 3.2.1.2 Support from international organizations
  - 3.2.1.3 Increased awareness and diagnosis
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of production
  - 3.2.2.2 Availability of alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Malaria Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Plasmodium falciparum
5.3 Plasmodium vivax
5.4 Plasmodium ovale
5.5 Plasmodium malariae
5.6 Plasmodium knowlesi

Chapter 6 Market Estimates and Forecast, By Product, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Antimalarial injections
6.3 Antimalarial tablets

Chapter 7 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Monotherapy
7.3 Combination therapy

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa